Use of anti-neuronal antibodies to diagnose paraneoplastic neurological syndromes
Gonzalez L, Augustovski F, Pichon-Riviere A, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L
Record ID 32016001125
Spanish
Authors' recommendations:
The evidence found supporting the use of anti-neuronal antibodies to diagnose paraneoplastic neurological syndromes is of low quality. The simultaneous use of antibodies shows low sensitivity and high specificity. In subjects with classical clinical manifestations, but without cancer diagnosis, its use could guide the search for underlying neoplasm and confirming their association.
Despite the fact that there is limited evidence, some expert consensuses support anti-Hu, Yo, CV2, Ri, Ma2, and amphiphysin antibody screening in patients with specific neurological manifestations without detectable neoplasm. They suggest their simultaneous investigation, since most syndromes are not specifically related to a particular type of antibody. Different United States private health sponsors authorize their screening in those subjects with neurological manifestations, when diagnostic doubts persist, and for those who meet specific criteria.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Humans
- Autoantibodies
- Paraneoplastic Syndromes
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.